[6-K] ASCENTAGE PHARMA GROUP INTERNATIONAL Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Ascentage Pharma Group International filed a Form 6-K noting plans to present clinical data at the 2025 American Society of Hematology (ASH) Annual Meeting. The company furnished two press releases dated November 3, 2025 and a Hong Kong Stock Exchange announcement dated November 4, 2025 as Exhibits 99.1, 99.2, and 99.3.

The disclosures state Ascentage will share results from multiple studies of olverembatinib and lisaftoclax, and additional data on APG-5918. One of the presentations has been selected for an oral report.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2025

Commission File Number: 001-42484

ASCENTAGE PHARMA GROUP INTERNATIONAL

(Translation of Registrant’s name into English)

68 Xinqing Road

Suzhou Industrial Park

Suzhou, Jiangsu

China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒            Form 40-F ☐

On November 3, 2025, Ascentage Pharma Group International (“Ascentage Pharma” or the “Company”) issued two press releases entitled, “Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025” and “Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025”. A copy of the press releases are furnished as Exhibits 99.1 and 99.2 to this Report. On November 4, 2025, Ascentage Pharma Group International posted an announcement on the Hong Kong Stock Exchange entitled, “Ascentage Pharma to Present Results from Multiple Clinical Studies of olverembatinib, lisaftoclax, APG-5918 at the 2025 American Society of Hematology (ASH) Annual Meeting, one of which have been selected for Oral Reports”. A copy of the announcement is furnished as Exhibit 99.3 to this Report.

1

INDEX TO EXHIBITS

Exhibit Number		Exhibit Title
99.1		Press release dated November 3, 2025
99.2		Press release date November 3, 2025
99.3		Announcement dated November 4, 2025

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASCENTAGE PHARMA GROUP INTERNATIONAL
Date: November 4, 2025	/s/ Dajun Yang
	Name:	Dajun Yang
	Title:	Chief Executive Officer

3

FAQ

What did Ascentage Pharma (AAPG) disclose in this 6-K?

It furnished two November 3, 2025 press releases and a November 4, 2025 HKEX announcement about planned ASH 2025 clinical data presentations.

Which programs will Ascentage Pharma present at ASH 2025?

The company will present results from studies of olverembatinib, lisaftoclax, and APG-5918.

Was any presentation selected for special format at ASH 2025?

Yes. One of the presentations has been selected for an oral report.

What exhibits are attached to the 6-K for AAPG?

Exhibit 99.1: press release (Nov 3, 2025); Exhibit 99.2: press release (Nov 3, 2025); Exhibit 99.3: HKEX announcement (Nov 4, 2025).

Does this filing include financial results or transactions?

No. It reports the furnishing of communications about upcoming scientific presentations.